Trump sexual misconduct allegations ‘remain very disturbing’: Republican senator

FAN Editor

Republican Sen. Susan Collins said sexual misconduct allegations against President Donald Trump that surfaced during the 2016 campaign “remain very disturbing.”

President Trump was not my choice for the Republican nominee for president, and I did not support him in part because of the way that all of these reports about how he was treating women,” the Maine senator told ABC News Chief Anchor George Stephanopoulos on “This Week” Sunday. “He is president now and I’m working with him on some issues. But those allegations remain very disturbing.”

At least 16 women have come forward alleging misconduct by Trump, ranging from sexual assault to harassment to inappropriate behavior.

Collins made her remarks after Stephanopoulos asked if she expected that the country will now see real change on sexual harassment with the current wave of allegations against prominent men from Hollywood to Washington, D.C.,

The senator responded that one problem is that some of the women making the allegations are getting attacked. “Their credibility is undermined,” she said.

Stephanopoulos brought up President Trump, saying, “More than a dozen women came forward during the campaign; [Trump] says that every single one of them are lying.” “He did say that,” Collins said.

At least eight women have accused Alabama Republican Senate candidate Roy Moore of sexual misconduct or inappropriate behavior, which Moore has repeatedly denied. Collins said she believes Moore’s accusers and hopes Alabama will not elect him to the Senate.

“I did not find him to be credible,” Collins said of Moore. “As more and more allegations come forward, that adds to the weight of evidence against him … I hope that the good voters of Alabama decide not to send him to the United States Senate.”

Free America Network Articles

Leave a Reply

Next Post

3 Biotech Stocks to Be Thankful for This Year

Anyone who has been holding onto shares of Loxo Oncology Inc. (NASDAQ: LOXO), Nektar Therapeutics (NASDAQ: NKTR), or Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) will have plenty to say when it’s their turn to share at the dinner table this Thanksgiving.  Continue Reading Below Surprisingly positive trial results for experimental cancer therapies helped shares […]

You May Like